Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 299

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma

Open access
Brown, Christine E., Aguilar, Brenda, Starr, Renate, Yang, Xin, Chang, Wen-Chung, Weng, Lihong, Chang, Brenda, Sarkissian, Aniee, Brito, Alfonso, Sanchez, James F., Ostberg, Julie R., D’Apuzzo, Massimo, Badie, Behnam, Barish, Michael E., Forman, Stephen J.·2018·Molecular Therapy
DOI 10.1016/j.ymthe.2017.10.002
Open this paper in CoChat — free account

Abstract

T cell immunotherapy is emerging as a powerful strategy to treat cancer and may improve outcomes for patients with glioblastoma (GBM). We have developed a chimeric antigen receptor (CAR) T cell immunotherapy targeting IL-13 receptor α2 (IL13Rα2) for the treatment of GBM. Here, we describe the optimization of IL13Rα2-targeted CAR T cells, including the design of a 4-1BB (CD137) co-stimulatory CAR (IL13BBζ) and a manufacturing platform using enriched central memory T cells. Utilizing orthotopic human GBM models with patient-derived tumor sphere lines in NSG mice, we found that IL13BBζ-CAR T cells improved anti-tumor activity and T cell persistence as compared to first-generation IL13ζ-CAR CD8 + T cells that had shown evidence for bioactivity in patients. Investigating the impact of corticosteroids, given their frequent use in the clinical management of GBM, we demonstrate that low-dose dexamethasone does not diminish CAR T cell anti-tumor activity in vivo. Furthermore, we found that local intracranial delivery of CAR T cells elicits superior anti-tumor efficacy as compared to intravenous administration, with intraventricular infusions exhibiting possible benefit over intracranial tumor infusions in a multifocal disease model. Overall, these findings help define parameters for the clinical translation of CAR T cell therapy for the treatment of brain tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2017.10.002

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 299

Metadata

Authors
Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., Ostberg, J. R., D’Apuzzo, M., Badie, B., Barish, M. E., & Forman, S. J.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2018-01
Volume
26
Issue
1
Pages
31-44
ISSN
1525-0016 (ISSN-L)
DOI
10.1016/j.ymthe.2017.10.002
OpenAlex
W2766649683
Cited by
299
References
48
FWCI
6.57
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. https://app.cochat.ai/papers/10.1016/j.ymthe.2017.10.002
The paper
Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., Ostberg, J. R., D’Apuzzo, M., Badie, B., Barish, M. E., & Forman, S. J. (2018). Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2017.10.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.